Related Experiment Video
Updated: Apr 30, 2026
Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine
Ji-Hong Lim1, Chi Luo2, Francisca Vazquez2
1Authors' Affiliations: Department of Cancer Biology, Dana-Farber Cancer Institute; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts; and Department of Biomedical Chemistry, College of Biomedical and Health Science, Konkuk University, Chungju, Chungbuk, Republic of Korea.
Abstract:
Metabolic targets offer attractive opportunities for cancer therapy. However, their targeting may activate alternative metabolic pathways that can still support tumor growth. A subset of human melanomas relies on PGC1α-dependent mitochondrial oxidative metabolism to maintain growth and survival. Herein, we show that loss of viability caused by suppression of PGC1α in these melanomas is rescued by induction of glycolysis. Suppression of PGC1α elevates reactive oxygen species levels decreasing hypoxia-inducible factor-1α (HIF1α) hydroxylation that, in turn, increases its protein stability. HIF1α reprograms melanomas to become highly glycolytic and dependent on this pathway for survival. Dual suppression of PGC1α and HIF1α causes energetic deficits and loss of viability that are partially compensated by glutamine utilization. Notably, triple suppression of PGC1α, HIF1α, and glutamine utilization results in complete blockage of tumor growth. These results show that due to high metabolic and bioenergetic flexibility, complete treatment of melanomas will require combinatorial therapy that targets multiple metabolic components.
Insights
Targeting melanoma's PGC1α pathway can be rescued by glycolysis. Combining PGC1α and HIF1α suppression, plus glutamine blockade, completely halts tumor growth by exploiting metabolic vulnerabilities.
Area of Science:
- Oncology
- Metabolic Pathways
- Cancer Metabolism
Background:
- Metabolic reprogramming is crucial for cancer growth and survival.
- Some melanomas depend on PGC1α-driven mitochondrial metabolism.
- Targeting metabolic pathways can lead to compensatory mechanisms, hindering therapeutic efficacy.
Purpose of the Study:
- To investigate the metabolic plasticity of melanomas.
- To identify compensatory metabolic pathways activated upon PGC1α suppression.
- To evaluate combinatorial therapeutic strategies targeting multiple metabolic vulnerabilities in melanoma.
Main Methods:
- Suppression of PGC1α and HIF1α (hypoxia-inducible factor-1α) in melanoma models.
- Analysis of metabolic pathway activation, including glycolysis and glutamine utilization.
- Assessment of tumor growth and cell viability under combinatorial metabolic inhibition.
Main Results:
- PGC1α suppression in melanoma leads to increased glycolysis via HIF1α stabilization.
- Dual PGC1α and HIF1α suppression induces metabolic deficits, partially compensated by glutamine.
- Combined targeting of PGC1α, HIF1α, and glutamine metabolism completely inhibits melanoma tumor growth.
Conclusions:
- Melanoma exhibits significant metabolic flexibility, utilizing alternative pathways to maintain viability.
- Targeting single metabolic pathways is insufficient for complete tumor eradication.
- Combinatorial therapies that simultaneously inhibit multiple metabolic dependencies, including PGC1α, HIF1α, and glutamine, are essential for effective melanoma treatment.
More Related Videos
Related Concept Videos
01:46Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
01:45Mitochondrial Membranes